Huawei Pursues AI-Driven Drug Development

Chinese company Huawei has announced an expansion of its collaboration with local pharmaceutical companies in the field of artificial intelligence, aiming to develop drugs and enhance clinical practice. This includes clinical applications and drug development stages, to strengthen its presence in the AI-powered drug discovery market. This move comes amid increasing demand for AI tools in pharmaceutical research and development, competing with American companies like NVIDIA, which have partnered with pharmaceutical firms to utilize AI in drug discovery. Huawei is among the leading companies providing tools to analyze potential drug compounds, testing its models in collaboration with pharmaceutical companies. It is also expected that machine learning could reduce the time and costs associated with drug development in the future.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل